Cancer drug resistance is still a major impediment (ex. about 30% breast cancer patients end up refractory). Limitations with chemotherapeutics & targeted therapeutic are largely due to resistance mechanisms. On one hand, the lack of breakthrough technologies in the field of drug conjugates is reducing therapeutic possibilities for clinicians. On the other hand, very promising perspectives are offered by both precision medicine and drug conjugates approach.
Hence, led by experienced team, and financially supported by serial entrepreneurs, Avicenna Oncology has been created with the purpose to combine both precision medicine and drug conjugates against resistant cancers. Located in Basel (Switzerland), the company has been founded in 2014, building upon an international network of collaborations and very promising programs.